The ReproSci project retrospectively analyzed the reproducibility of 1006 claims from 400 papers published between 1959 and 2011 in the field of Drosophila immunity. This project attempts to provide a ...
Tabular foundation models are the next major unlock for AI adoption, especially in industries sitting on massive databases of ...
CRANBROOK, BRITISH COLUMBIA / ACCESS Newswire / January 15, 2026 / Eagle Plains Resources Ltd. (TSXV:EPL)(OTCQB:EGPLF) ...
The orbitofrontal cortex (OFC) is critical to identifying task structure and to generalizing appropriately across task states with similar underlying or hidden causes. This capability is at the heart ...
What would you do with a vacant county courthouse? Santa Rosa developers offer plans that would revitalize downtown Milton.
TALLAHASSEE, Fla. (WCTV) - College football looks more like its big brother the NFL with each passing season, now with the advent of contracts and direct compensation it’s closer than ever, after a ...
Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback